Name and Address of Reporting Person  
Silber Christopher  
(First) 
VIGIL NEUROSCIENCE, INC.  
100 FORGE ROAD, SUITE 700  
(Watertown) MA 02472  

Issuer Name and Ticker or Trading Symbol  
Vigil Neuroscience, Inc. [VIGL]  

Date of Earliest Transaction (Month/Day/Year)  
08/07/2023  

Relationship of Reporting Person(s) to Issuer  
X Officer (give title below)  
Chief Medical Officer  

Transaction Date (Month/Day/Year)  
08/07/2023  

Individual or Joint/Group Filing (Check Applicable Line)  
X Form filed by One Reporting Person  

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned  

<table>
<thead>
<tr>
<th>Title of Security</th>
<th>Transaction Date (Month/Day/Year)</th>
<th>Deemed Execution Date, if any (Month/Day/Year)</th>
<th>Transaction Code (Instr. 8)</th>
<th>Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)</th>
<th>Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)</th>
<th>Ownership Form: Direct (D) or Indirect (I) (Instr. 4)</th>
<th>Nature of Indirect Beneficial Ownership (Instr. 4)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Stock Option</td>
<td>$6.16</td>
<td>08/07/2023</td>
<td>A</td>
<td>330,000 (1)</td>
<td>330,000 (1)</td>
<td>D</td>
<td>** Common Stock **</td>
</tr>
</tbody>
</table>

** Stock Option Grant (Right to Buy) **  

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned  
(e.g., puts, calls, warrants, options, convertible securities)  

<table>
<thead>
<tr>
<th>Title of Derivative Security (Instr. 3)</th>
<th>Conversion or Exercise Price of Derivative Security</th>
<th>Transaction Date (Month/Day/Year)</th>
<th>Deemed Execution Date, if any (Month/Day/Year)</th>
<th>Transaction Code (Instr. 8)</th>
<th>Number of Derivative Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)</th>
<th>Date Exercisable and Expiration Date (Month/Day/Year)</th>
<th>Title of Underlying Derivative Security (Instr. 3 and 4)</th>
<th>Amount or Number of Shares</th>
<th>Ownership Form: Direct (D) or Indirect (I) (Instr. 4)</th>
<th>Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)</th>
<th>Nature of Indirect Beneficial Ownership (Instr. 4)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Stock Option</td>
<td>$6.16</td>
<td>08/07/2023</td>
<td>A</td>
<td>330,000 (1)</td>
<td>330,000 (1)</td>
<td>08/07/2033</td>
<td>Common Stock</td>
<td>330,000 (1)</td>
<td>D</td>
<td>330,000 (1)</td>
<td>** Common Stock **</td>
</tr>
</tbody>
</table>

** Explanation of Responses: **  
1. This stock option award was issued pursuant to the Issuer’s 2021 Stock Option and Incentive Plan and shall vest as follows: 25% of the shares shall be vested on August 7, 2024 and 1/36th of the remaining shares shall vest on each monthly anniversary thereafter.  

** Remarks: **  
/~/ Christopher Verni, Attorney-in-Fact  
08/07/2023  
** Signature of Reporting Person **  

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.  
If the form is filed by more than one reporting person, see Instruction 4 (b)(v).  
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.  
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.